Abstract
We evaluated the use of a new, controlled-release capsule form of carbamazepine, Carbatrol capsules, in an open-label, multicenter study of 124 patients with complex partial seizures. Ninety-one percent of the patients successfully completed the 6-month trial with good seizure control, with a significant improvement in quality of life. We conclude that switching patients with complex partial seizures from multiple daily-dose carbamazepine to twice-daily Carbatrol on a milligram-to-milligram basis is relatively safe.
Original language | English (US) |
---|---|
Pages (from-to) | 1727-1729 |
Number of pages | 3 |
Journal | Neurology |
Volume | 51 |
Issue number | 6 |
DOIs | |
State | Published - Dec 1998 |
Externally published | Yes |
ASJC Scopus subject areas
- Clinical Neurology